Kymera Therapeutics, Inc. (KYMR) just reported positive results from its phase 1 healthy volunteer study using KT-621. The purpose of this clinical candidate is to develop it as an oral STAT6 protein ...

Monte Rosa Therapeutics, Inc. has initiated a Phase 1 study for MRT-8102, a novel molecular glue degrader targeting the NEK7 protein to treat inflammatory conditions linked to the NLRP3 inflammasome.

Neumora Therapeutics, Inc. has announced the initiation of a Phase 1 study for NMRA-861, a potent and selective positive allosteric modulator of the M4 muscarinic receptor, aimed at treating ...

Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) -Clinical data to date supports a potentially ...